COMMUNIQUÉS West-GlobeNewswire

Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
06/08/2026
- VIRAGE2 exploratory study designed to refine the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial in metastatic pancreatic ductal adenocarcinoma (PDAC) - - Study builds on [...]
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
06/08/2026
Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved Targeted Therapy to [...]
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
06/08/2026
Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants. SLIM-1 ™ trial is a Phase 1, randomized, controlled clinical trial design to characterize [...]
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
06/08/2026
Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND‑100 in patients with Alcohol Use Disorder (AUD) - a key milestone in the [...]
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
06/08/2026
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to [...]
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
06/08/2026
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast [...]
LENSAR® to Report Second Quarter 2026 Results on August 13th, 2026
06/08/2026
ORLANDO, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, [...]
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
06/08/2026
-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 -- -- Favorable [...]
Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments
06/08/2026
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing Completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease; [...]
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
06/08/2026
Obesity Treatment Candidate Designed to Preserve Lean Body Mass Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc [...]
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
06/08/2026
People with AAE-C1INH experience frequent misdiagnoses, emergency medical events, and wide-ranging impact on physical, emotional, and social well-being Study results informed the design and endpoint selection of the [...]
Zelluna ASA: Disclosure of large shareholding
06/08/2026
Reference is made to the stock exchange announcement published by Zelluna ASA (the "Company") on 4 August 2026 regarding the issuance of 446,752 new shares to Inven2 AS. Birk Venture AS currently holds 1,488,507 shares [...]
Enovis Announces Second Quarter 2026 Results
06/08/2026
Second-quarter sales growth of 3% on a reported basis, 5% organic Second-quarter Reconstructive sales grew 8% on a reported basis, 6% organic Reaffirmed full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS [...]
Shape Therapeutics and Rett Syndrome Research Trust Announce Partnership to Advance a One-Time AI-Designed RNA Editing Therapy for Rett Syndrome
06/08/2026
Collaboration will evaluate Shape's intravenously delivered RNAfix ® gene therapy designed to correct the MECP2 R168X mutation in non-human primates (NHP) SEATTLE, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Shape Therapeutics, a [...]
Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results
06/08/2026
2Q’26 Net Income of $9.0M, +236.7% from 2Q’25 2Q’26 Adjusted EBITDA of $37.4M, +29.1% from 2Q’25 Full-Year 2026 Guidance Raised for All Key Financial Metrics ARLINGTON, Va., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Privia [...]
LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook
06/08/2026
Announces $100 Million Share Repurchase Program SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
06/08/2026
Bagsværd, Denmark, 6 August 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]
Actimed Therapeutics Reacquires Global Rights to S-oxprenolol, Broadening Pipeline Opportunity
06/08/2026
London, UK – 6 th August 2026. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting [...]
IBA Notice of Half Year 2026 Results and Conference Call
06/08/2026
HY26 results webcast to take place on Thursday, 27 August 2026 at 3 p.m. CEST Louvain-la-Neuve, Belgium, 6 August 2026, 7 a.m. - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator [...]

Pages